Government officials in Rajasthan are investigating a series of maternal deaths occurring at public hospitals in Kota, Bikaner, and Jodhpur.
The surge in fatalities raises urgent questions about the safety of public healthcare infrastructure and the quality of pharmaceutical supplies provided to expecting mothers.
Reports indicate 18 maternal deaths have occurred across the state since May [1]. This includes a recent spike of nine deaths within a six-day period [1]. Another report noted seven women died following childbirth over a period of less than two months [2].
Investigators are examining possible lapses in hospital protocols, including infection control, and post-operative care. The deaths have prompted multiple government inquiries to determine if systemic failures in public health facilities contributed to the fatalities.
Parallel to the hospital probes, authorities have focused on drug safety. The government canceled the manufacturing license for M/s Jackson Laboratories Private Limited [2]. This action follows investigations into whether contaminated or substandard medications played a role in the patient deaths.
Public health officials are now reviewing the procurement and distribution of drugs used in maternity wards. The investigation aims to identify if the pharmaceutical failure was isolated to one facility or widespread across the state's government hospital network.
“18 maternal deaths have occurred across the state since May”
This situation highlights a critical intersection between pharmaceutical regulation and clinical oversight in India's public health system. The cancellation of a manufacturing license suggests that the government suspects a systemic product failure rather than purely clinical errors, indicating that drug quality control may be a primary vulnerability in regional maternal care.
